In the present study we evaluated PCI of the HER2-targeted single chain antibody-based recombinant immunotoxin MH3-B1/rGel in three ovarian cancer cell lines, generally resistant to HER2-targeted therapy, and also on ovarian cancer xenografts in athymic mice. The gene discussed is ERBB2; the disease is ovarian carcinoma.